$PULM
Pulmatrix, Inc. Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000119312518237285 Filed on August 03, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.770M	$2.120M	$2.070M
YoY Change	-12.38%	2.42%	-6.33%
% of Gross Profit
Research & Development	$3.056M	$4.013M	$3.363M
YoY Change	16.73%	19.33%	37.77%
% of Gross Profit
Depreciation & Amortization	$60.00K	$60.00K	$70.00K
YoY Change	0.0%	-14.29%	16.67%
% of Gross Profit
Operating Expenses	$4.825M	$6.128M	$5.429M
YoY Change	4.01%	12.88%	-41.18%
Operating Profit	-$4.825M	-$6.128M	-$5.429M
YoY Change	12.11%	12.88%	-39.48%
Interest Expense	$0.00	$80.00K	$172.0K
YoY Change	-100.0%	-53.49%	-23.21%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$20.00K	$4.000K
YoY Change	-80.0%	400.0%	-42.86%
Pretax Income	-$4.820M	-$6.190M	-$5.600M
YoY Change	8.31%	10.54%	-39.06%
Income Tax
% Of Pretax Income
Net Earnings	-$4.816M	-$6.188M	-$5.597M
YoY Change	8.18%	10.56%	-39.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.028M	-$1.343M	-$2.857M
COMMON SHARES
Basic Shares Outstanding	46.93M shares	41.93M shares	19.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.810M	$8.340M	$10.98M
YoY Change	-40.09%	-24.04%	1.76%
Cash & Equivalents	$3.806M	$8.341M	$10.98M
Short-Term Investments
Other Short-Term Assets	$910.0K	$620.0K	$750.0K
YoY Change	2.25%	-17.33%	264.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.720M	$8.960M	$11.73M
YoY Change	-37.48%	-23.61%	-0.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$447.0K	$498.0K	$672.0K
YoY Change	-31.96%	-25.89%	-23.2%
Goodwill	$10.91M	$10.91M	$10.91M
YoY Change	0.0%	0.0%	-31.54%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$11.57M	$11.62M	$11.79M
YoY Change	-1.78%	-1.48%	-30.73%
TOTAL ASSETS
Total Short-Term Assets	$4.720M	$8.960M	$11.73M
Total Long-Term Assets	$11.57M	$11.62M	$11.79M
Total Assets	$16.29M	$20.58M	$23.52M
YoY Change	-15.73%	-12.52%	-18.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.367M	$1.507M	$564.0K
YoY Change	33.11%	167.2%	-15.06%
Accrued Expenses	$2.284M	$2.271M	$2.583M
YoY Change	43.92%	-12.08%	113.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$2.745M
YoY Change			22.93%
Total Short-Term Liabilities	$3.651M	$3.778M	$5.892M
YoY Change	-43.92%	-35.88%	43.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.804M
YoY Change		-100.0%	-60.33%
Other Long-Term Liabilities			$40.00K
YoY Change			300.0%
Total Long-Term Liabilities	$0.00	$0.00	$1.804M
YoY Change	-100.0%	-100.0%	-60.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.651M	$3.778M	$5.892M
Total Long-Term Liabilities	$0.00	$0.00	$1.804M
Total Liabilities	$3.650M	$3.780M	$7.731M
YoY Change	-44.23%	-51.11%	-10.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$190.2M	-$185.4M	-$165.0M
YoY Change	12.24%	12.35%	15.44%
Common Stock	$202.9M	$202.2M	$180.8M
YoY Change	11.3%	11.83%	10.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.63M	$16.80M	$15.79M
YoY Change
Total Liabilities & Shareholders Equity	$16.29M	$20.58M	$23.52M
YoY Change	-15.73%	-12.52%	-18.39%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$4.816M	-$6.188M	-$5.597M
YoY Change	8.18%	10.56%	-39.08%
Depreciation, Depletion And Amortization	$60.00K	$60.00K	$70.00K
YoY Change	0.0%	-14.29%	16.67%
Cash From Operating Activities	-$4.520M	-$4.950M	-$3.660M
YoY Change	-2.16%	35.25%	-5.18%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$0.00	-$10.00K
YoY Change	-66.67%	-100.0%	-90.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	$0.00	-$10.00K
YoY Change	-66.67%	-100.0%	-90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	11.74M	4.110M
YoY Change	-150.0%	185.64%
NET CHANGE
Cash From Operating Activities	-4.520M	-4.950M	-3.660M
Cash From Investing Activities	-10.00K	0.000	-10.00K
Cash From Financing Activities	-10.00K	11.74M	4.110M
Net Change In Cash	-4.540M	6.790M	440.0K
YoY Change	-1.94%	1443.18%	-111.11%
FREE CASH FLOW
Cash From Operating Activities	-$4.520M	-$4.950M	-$3.660M
Capital Expenditures	-$10.00K	$0.00	-$10.00K
Free Cash Flow	-$4.510M	-$4.950M	-$3.650M
YoY Change	-1.74%	35.62%	-2.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46927221	shares
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2271000
CY2018Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	119000
CY2018Q2	us-gaap	Assets Current AssetsCurrent	8960000
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	202204000
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1507000
CY2018Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1000
CY2018Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1085000
CY2018Q2	us-gaap	Assets Assets	20576000
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8341000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8341000
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46927221	shares
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46927221	shares
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	5000
CY2018Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0
CY2018Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	67000
CY2018Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	101000
CY2018Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4849000
CY2017Q4	us-gaap	Assets Assets	15978000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3550000
CY2018Q2	us-gaap	Goodwill Goodwill	10914000
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3778000
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20576000
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	90000
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	698000
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1701000
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	676000
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	327000
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Prepaid Insurance PrepaidInsurance	371000
CY2018Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	146000
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	498000
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	619000
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185411000
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.34
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10215212	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3948954	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.18
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10395657	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.32
CY2018Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	16798000
CY2018Q2	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	61000
CY2018Q2	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	849000
CY2018Q2	pulm	Debt Instrument Accretion Of Debt Discount DebtInstrumentAccretionOfDebtDiscount	35000
CY2018Q2	pulm	Working Capital Deficit WorkingCapitalDeficit	5182000
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10976000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4182000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2162000
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	57000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4246000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	184137000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	457000
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1113000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3550000
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21047498	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21047498	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3221000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	35000
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	68000
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1000
CY2017Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	27000
CY2017Q4	us-gaap	Goodwill Goodwill	10914000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5841000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15978000
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3221000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70000
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	204000
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	44000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	614000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	696000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	204000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174002000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3695634	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.69
CY2017Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10137000
CY2017Q4	pulm	Accrued Legal And Patent Current AccruedLegalAndPatentCurrent	61000
CY2017Q4	pulm	Accrued Clinical And Consulting Current AccruedClinicalAndConsultingCurrent	568000
CY2017Q4	pulm	Accrued End Of Term Fee AccruedEndOfTermFee	225000
CY2017Q4	pulm	Prepaid Clinical Trials PrepaidClinicalTrials	421000
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	3259000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3000
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>2. Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation <font style="WHITE-SPACE: nowrap">S-X,</font> Rule <font style="WHITE-SPACE: nowrap">10-01.</font> Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months and six months ended June 30, 2018, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2018. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2017, which are included in the Company’s annual report on Form <font style="WHITE-SPACE: nowrap">10-K</font> filed with the SEC on March 13, 2018.</p> </div>
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4791000
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	3000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	118000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Type DocumentType	10-Q
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
	dei	Entity Registrant Name EntityRegistrantName	Pulmatrix, Inc.
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4161000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1050000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-77000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	334000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	6977	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M26D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Revenues Revenues	153000
	us-gaap	Share Based Compensation ShareBasedCompensation	1698000
	us-gaap	Interest Expense InterestExpense	186000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12868000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8075000
	us-gaap	Net Income Loss NetIncomeLoss	-11409000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000
	us-gaap	Operating Expenses OperatingExpenses	11395000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11242000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-3259000
	us-gaap	Profit Loss ProfitLoss	-11409000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7234000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	1698000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6707000	shares
	dei	Trading Symbol TradingSymbol	PULM
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y11M23D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34056434	shares
	pulm	Non Cash Interest Expenses NonCashInterestExpenses	55000
	pulm	Fair Value Adjustment On Derivative Liability FairValueAdjustmentOnDerivativeLiability	-1000
	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	16372000
	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	0
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6649000
	us-gaap	Net Income Loss NetIncomeLoss	-9080000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000
	us-gaap	Operating Expenses OperatingExpenses	8741000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8741000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	304000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1315000
	us-gaap	Profit Loss ProfitLoss	-9080000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5035000
	us-gaap	Share Based Compensation ShareBasedCompensation	1337000
	pulm	End Of Term Payments EndOfTermPayments	-245000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6794000
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	7000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	127000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3706000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-183000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1215000
	us-gaap	Interest Expense InterestExpense	359000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13456000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	1324000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18179951	shares
	pulm	Non Cash Interest Expenses NonCashInterestExpenses	94000
	pulm	Noncash Rent Expense NoncashRentExpense	11000
	pulm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	14467000
CY2015	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	11000
CY2017	pulm	Fair Value Of Warrant Derivative Liabilities At Issuance Recorded As Debt Discount FairValueOfWarrantDerivativeLiabilitiesAtIssuanceRecordedAsDebtDiscount	1000
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2115000
CY2018Q2	us-gaap	Interest Expense InterestExpense	80000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-6188000
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	6128000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6128000
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4013000
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	933000
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46102043	shares
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2066000
CY2017Q2	us-gaap	Interest Expense InterestExpense	172000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5597000
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	5429000
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5429000
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3363000
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	709000
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19553281	shares

Files In Submission

Name	View Source	Status
0001193125-18-237285-index-headers.html	Edgar Link	pending
0001193125-18-237285-index.html	Edgar Link	pending
0001193125-18-237285.txt	Edgar Link	pending
0001193125-18-237285-xbrl.zip	Edgar Link	pending
d495860d10q.htm	Edgar Link	pending
d495860dex311.htm	Edgar Link	pending
d495860dex312.htm	Edgar Link	pending
d495860dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pulm-20180630.xml	Edgar Link	completed
pulm-20180630.xsd	Edgar Link	pending
pulm-20180630_cal.xml	Edgar Link	unprocessable
pulm-20180630_def.xml	Edgar Link	unprocessable
pulm-20180630_lab.xml	Edgar Link	unprocessable
pulm-20180630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix, Inc. Stock $pulm

2018 Q3 Form 10-Q Financial Statement

#000119312518237285 Filed on August 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix, Inc. Stock $pulm

2018 Q3 Form 10-Q Financial Statement

#000119312518237285 Filed on August 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix, Inc. Stock $pulm